|
An exciting business intelligence service designed to keep you in touch with the latest developments in the central nervous system drug market
Industry interest in the conditions of the central nervous system is at an all time high. But it is those illnesses affecting the elderly - specifically Alzheimer's disease, Parkinson's disease and Stroke - which are driving clinical development. And interest is likely to stay high, with the number of elderly people - particularly in the critical over 80 age group - set to increase over the next 25 years.
More than ever before, CNS drugs are taking a central position in industry's research efforts. That is why Espicom Business Intelligence has launched this major business information service, CNS Drug News.
CNS Drug News takes the hard work and effort out of staying in touch with the companies, products, alliances and research that are shaping the global Central Nervous System market. Incorporating primary source material, augmented with data from Espicom's unique intelligence base, CNS Drug News provides a compelling, easy-to-read route to providing market knowledge.
The following sections appear in every issue:
- General Development News
- Conference Listings
A selection of the following topics will appear each month, depending on news availability:
- Neurodegenerative Disorders
- Anxiolytics/Sleep Disorders
- Antidepressants
- Psychotic Disorders
- Analgesics/Anaesthetics
- Therapies to Treat Substance Dependence
- Anti-epileptics
- Drugs used in Nausea & Vertigo
- Eating Disorders
- Cerebrovascular Disorders
- Plus R&D highlights from International Conferences
|
